The drugmaker's stock soared last month on a rich buyout offer from Japan's Takeda Pharmaceutical.
News & Analysis: Ariad Pharmaceuticals
Find out why these stocks have soared during the post-election rally.
Despite market losses, these stocks gained ground. Find out why.
Ariad Pharmaceuticals finally finds a suitor.
Post-election optimism that regulators will dial back rhetoric regarding drug prices rekindled investors' interest last month.
The company drew the ire of Bernie Sanders last month, sending its shares spiraling downwards.
Milestone payments from partner Eisai help Arena perform better in Q3 than expected.
Ariad topped expectations in Q3. Here's how the biotech did it.
Even though the market managed to gain ground, these stocks fell. Find out why.
Worry over mounting political scrutiny of its pricing of Iclusig led investors to head for the exits today.